SHAREHOLDERS' EQUITY |
3 Months Ended | 12 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 |
Dec. 31, 2025 |
|||||||||||||||||||
| Equity [Abstract] | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY |
NOTE
6 - SHAREHOLDERS’ EQUITY:
Sales
Under ATM
On
September 26, 2025 the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with a sales agent.
In accordance with the terms of the Sales Agreement, the Company may offer and sell up to $13,170 of
its newly issued ordinary shares from time to time through the sales agent.
The
sales agent will not sell ordinary shares unless instructed by the Company and will use commercially reasonable efforts to sell on the
Company’s behalf all of the ordinary shares requested to be sold by the Company, subject to the terms of the Sales Agreement.
The
sales agent will be entitled to cash compensation equal to 3.0%
of the gross sales price of ordinary shares sold under the Sales Agreement.
On
March 25, 2026, the Company issued and sold 6,408
ordinary shares for $76,
net of issuance costs (including utilization of prepaid transaction expenses of $7
and placement agent fee), under the Sales Agreement for the Company’s ATM facility. For further details regarding additional amounts
raised following the reporting period, see Note 12(a).
|
NOTE
9 - SHAREHOLDERS’ EQUITY:
The
ordinary shares of Silexion confer upon their holders the right to participate and vote in general meetings of Silexion and to share in
the distribution of dividends, if any, declared by Silexion.
On
September 26, 2025 the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with a sales agent.
In accordance with the terms of the Sales Agreement, the Company may offer and sell up to $13,170
of its newly issued ordinary shares from time to time through the sales agent.
The
sales agent will not sell ordinary shares unless instructed by the Company and will use commercially reasonable efforts to sell on the
Company’s behalf all of the ordinary shares requested to be sold by the Company, subject to the terms of the Sales Agreement.
The
sales agent will be entitled to cash compensation equal to 3.0%
of the gross sales price of ordinary shares sold under the Sales Agreement. As of December 31, 2025, no ordinary shares had been sold
under the Sales Agreement.
|